

**Remarks**

Following entry of an Examiner's amendment, claims 1, 4, 5, 11-22, and 41-72 were allowed by the Examiner in the Notice of Allowance mailed October 17, 2007.

The above amendments clarify the scope of claims 49 and 50 following entry of the Examiner's amendments. Applicants submit that the requested amendments merely embody the correction or clarification of formal matters. Further, the requested amendments do not change the scope of any independent claim or the overall scope of the claims.

Applicants respectfully request entry of these amendments under 37 C.F.R. § 1.312.

A description of the amendments to each claim follows.

**Amendments to Claim 49**

In the Examiner's Amendment for claim 49, the Examiner replaced "treating" with "inhibiting RAGE" as shown below:

49. A method for ~~treating~~ inhibiting RAGE a disease state selected from the group consisting of . . .

In the amendments requested above for claim 49, Applicants have accepted the Examiner's amendment and added the phrase "in a subject having" as shown below:

49. A method for inhibiting RAGE in a subject having a disease state selected from the group consisting of . . .

**Amendments to Claim 50**

In the Examiner's Amendment for claim 50, the Examiner replaced "of prevention and/or treatment of" with "inhibiting RAGE in a" as shown below:

Amendment under § 1.312  
App. Ser. No. 10/091,759  
Page 27 of 27

50. A method ~~of prevention and/or treatment of~~ inhibiting RAGE in a RAGE mediated human diseases comprising . . .

In the amendments requested above for claim 50, Applicants have accepted the Examiner's amendment, added "of", and the phrase "human having a" as well as changing "diseases" to "disease" as shown below:

50. A method of inhibiting RAGE in a human having a RAGE mediated human ~~diseases~~ disease comprising . . .

### **Fees**

This response is being timely filed before the due date of payment of the issue fee. No fee is believed due, however, should a fee be deemed to be necessary, the Commissioner is hereby authorized to charge any fees required by this action or any future action to Deposit Account No. 50-3216.

### **Conclusion**

In conclusion, Applicants request entry of the amendments, consideration of the Remarks, a Supplemental Notice of Allowance, and passage of the application to issuance.

Should the Examiner have any questions relating to the instant application, the Examiner is invited to telephone the undersigned at (336) 841-0300 ext. 159 to discuss any issues.

Respectfully submitted,

Date: November 8, 2007

/Samuel B. Rollins/  
Samuel B. Rollins (Reg. No. 52,180)

TransTech Pharma, Inc.  
4170 Mendenhall Oaks Pkwy  
High Point, NC 27265  
Ph: 336-841-0300 ext. 159  
Fax: 336-841-0310